These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

360 related articles for article (PubMed ID: 30300581)

  • 1. Enhanced Anti-lymphoma Activity of CAR19-iNKT Cells Underpinned by Dual CD19 and CD1d Targeting.
    Rotolo A; Caputo VS; Holubova M; Baxan N; Dubois O; Chaudhry MS; Xiao X; Goudevenou K; Pitcher DS; Petevi K; Kachramanoglou C; Iles S; Naresh K; Maher J; Karadimitris A
    Cancer Cell; 2018 Oct; 34(4):596-610.e11. PubMed ID: 30300581
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enhancing the antitumor functions of invariant natural killer T cells using a soluble CD1d-CD19 fusion protein.
    Das R; Guan P; Wiener SJ; Patel NP; Gohl TG; Evans E; Zauderer M; Nichols KE
    Blood Adv; 2019 Mar; 3(5):813-824. PubMed ID: 30858151
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activated invariant natural killer T cells directly recognize leukemia cells in a CD1d-independent manner.
    Aoki T; Takami M; Takatani T; Motoyoshi K; Ishii A; Hara A; Toyoda T; Okada R; Hino M; Koyama-Nasu R; Kiuchi M; Hirahara K; Kimura MY; Nakayama T; Shimojo N; Motohashi S
    Cancer Sci; 2020 Jul; 111(7):2223-2233. PubMed ID: 32324315
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low-cost generation of Good Manufacturing Practice-grade CD19-specific chimeric antigen receptor-expressing T cells using piggyBac gene transfer and patient-derived materials.
    Ramanayake S; Bilmon I; Bishop D; Dubosq MC; Blyth E; Clancy L; Gottlieb D; Micklethwaite K
    Cytotherapy; 2015 Sep; 17(9):1251-67. PubMed ID: 26212611
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Human CD4
    Baiu DC; Sharma A; Schehr JL; Basu J; Smith KA; Ohashi M; Johannsen EC; Kenney SC; Gumperz JE
    Immunology; 2024 Aug; 172(4):627-640. PubMed ID: 38736328
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Retinoic acid induction of CD1d expression primes chronic lymphocytic leukemia B cells for killing by CD8
    Ghnewa YG; O'Reilly VP; Vandenberghe E; Browne PV; McElligott AM; Doherty DG
    Clin Immunol; 2017 Oct; 183():91-98. PubMed ID: 28780376
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination of NKT14m and Low Dose IL-12 Promotes Invariant Natural Killer T Cell IFN-γ Production and Tumor Control.
    Guan P; Schaub R; Nichols KE; Das R
    Int J Mol Sci; 2020 Jul; 21(14):. PubMed ID: 32708464
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Navigating the Role of CD1d/Invariant Natural Killer T-cell/Glycolipid Immune Axis in Multiple Myeloma Evolution: Therapeutic Implications.
    Papoutselis M; Spanoudakis E
    Clin Lymphoma Myeloma Leuk; 2020 Jun; 20(6):358-365. PubMed ID: 32234294
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Human dendritic cells derived from embryonic stem cells stably modified with CD1d efficiently stimulate antitumor invariant natural killer T cell response.
    Zeng J; Wang S
    Stem Cells Transl Med; 2014 Jan; 3(1):69-80. PubMed ID: 24292792
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-CD79b/CD3 bispecific antibody combined with CAR19-T cells for B-cell lymphoma treatment.
    Zheng WW; Zhou H; Li P; Ye SG; Abudureheman T; Yang LT; Qing K; Liang AB; Chen KM; Duan CW
    Cancer Immunol Immunother; 2023 Nov; 72(11):3739-3753. PubMed ID: 37707586
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PD-1 checkpoint inhibition enhances the antilymphoma activity of CD19-CAR-iNKT cells that retain their ability to prevent alloreactivity.
    Moraes Ribeiro E; Secker KA; Nitulescu AM; Schairer R; Keppeler H; Wesle A; Schmid H; Schmitt A; Neuber B; Chmiest D; Podavini S; Märklin M; Klimovich B; Schmitt M; Korkmaz F; Lengerke C; Schneidawind C; Schneidawind D
    J Immunother Cancer; 2024 Jan; 12(1):. PubMed ID: 38296597
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Parallel CD19/CD20 CAR-Activated T-Cells Are More Effective for Refractory B-Cell Lymphoma In Vitro and In Vivo.
    Yin Y; Zhang P; He L; Guo X; Wang H; Li J; Xu Q
    Evid Based Complement Alternat Med; 2022; 2022():1227308. PubMed ID: 36034960
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Potent CD1d-binding Glycolipid for iNKT-Cell-based Therapy Against Human Breast Cancer.
    Seki T; Liu J; Brutkiewicz RR; Tsuji M
    Anticancer Res; 2019 Feb; 39(2):549-555. PubMed ID: 30711929
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Construction and evaluation of dual-effect cord blood natural killer cells expressing highaffinity PD-1 and chimeric antigen CD19 receptor].
    Zhong H; Zou Q; Liu H; Wang X; DU S; Liang H; Wu Z; Ye J; Zou Q
    Nan Fang Yi Ke Da Xue Xue Bao; 2021 Dec; 41(12):1877-1884. PubMed ID: 35012922
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Invariant NKT cells contribute to chronic lymphocytic leukemia surveillance and prognosis.
    Gorini F; Azzimonti L; Delfanti G; Scarfò L; Scielzo C; Bertilaccio MT; Ranghetti P; Gulino A; Doglioni C; Di Napoli A; Capri M; Franceschi C; Caligaris-Cappio F; Ghia P; Bellone M; Dellabona P; Casorati G; de Lalla C
    Blood; 2017 Jun; 129(26):3440-3451. PubMed ID: 28465341
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PiggyBac-Engineered T Cells Expressing CD19-Specific CARs that Lack IgG1 Fc Spacers Have Potent Activity against B-ALL Xenografts.
    Bishop DC; Xu N; Tse B; O'Brien TA; Gottlieb DJ; Dolnikov A; Micklethwaite KP
    Mol Ther; 2018 Aug; 26(8):1883-1895. PubMed ID: 29861327
    [TBL] [Abstract][Full Text] [Related]  

  • 17. JNK2 modulates the CD1d-dependent and -independent activation of iNKT cells.
    Liu J; Gallo RM; Khan MA; Iyer AK; Kratzke IM; Brutkiewicz RR
    Eur J Immunol; 2019 Feb; 49(2):255-265. PubMed ID: 30467836
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Functional invariant natural killer T-cell and CD1d axis in chronic lymphocytic leukemia: implications for immunotherapy.
    Weinkove R; Brooks CR; Carter JM; Hermans IF; Ronchese F
    Haematologica; 2013 Mar; 98(3):376-84. PubMed ID: 23065503
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A locus on mouse chromosome 13 inversely regulates CD1d expression and the development of invariant natural killer T-cells.
    Tsaih SW; Presa M; Khaja S; Ciecko AE; Serreze DV; Chen YG
    Genes Immun; 2015; 16(3):221-30. PubMed ID: 25654212
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CD1d-Restricted pathways in hepatocytes control local natural killer T cell homeostasis and hepatic inflammation.
    Zeissig S; Peuker K; Iyer S; Gensollen T; Dougan SK; Olszak T; Kaser A; Blumberg RS
    Proc Natl Acad Sci U S A; 2017 Sep; 114(39):10449-10454. PubMed ID: 28893990
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.